A child with laryngo-onychocutaneous syndrome partially responsive to treatment with thalidomide

British Journal of Dermatology

Volumn 155, Issue 6, 2006, Pages 1283-1286

  Strauss, R M ^a   Bate J ^a   Nischal, K K ^b   Clayton, T ^a   Gooi, J ^a   Darling, J C ^a   Newton Bishop, J A ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

Granulation tissue; Laryngo onychocutaneous syndrome; Shabbir syndrome; Thalidomide

Indexed keywords

CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; THALIDOMIDE;

ADOLESCENT; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; CASE REPORT; CLINICAL FEATURE; DRUG DOSE REGIMEN; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GRANULATION TISSUE; HUMAN; LARYNGOONYCHOCUTANEOUS SYNDROME; LARYNX DISORDER; NAIL DYSTROPHY; PRIORITY JOURNAL; RELAPSE; SKIN ULCER; THERAPY EFFECT; TRACHEA MUCUS; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; CONJUNCTIVAL DISEASES; EPIDERMOLYSIS BULLOSA; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LARYNGEAL DISEASES; NAIL DISEASES; SYNDROME; THALIDOMIDE; ULCER;

EID: 33750929726     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07464.x     Document Type: Article

References (15)

1. Shabbir G, Hassan M, Kazmi A. Laryngo-onycho-cutaneous syndrome. Biomedica 1986; 2:15-25.
2. Phillips RJ, Atherton DJ, Gibbs ML et al. Laryngo-onycho-cutaneous syndrome: an inherited epithelial defect. Arch Dis Child 1994; 70:319-26.
3. Ainsworth JR, Shabbir G, Spencer AF, Cockburn F. Multisystem disorder of Punjabi children exhibiting spontaneous dermal and submucosal granulation tissue formation: LOGIC syndrome. Clin Dysmorphol 1992; 1:3-14.
4. Ainsworth JR, Spencer AF, Dudgeon J et al. Laryngeal and ocular granulation tissue formation in two Punjabi children: LOGIC syndrome. Eye 1991; 5:717-22.
5. Moore JE, Dua HS, Page AB et al. Ocular surface reconstruction in LOGIC syndrome by amniotic membrane transplantation. Cornea 2001; 20:753-6.
6. Phillips RJ, Aplin JD, Lake BD. Antigenic expression of integrin alpha 6 beta 4 in junctional epidermolysis bullosa. Histopathology 1994; 24:571-6.
7. McGrath JA, Kivirikko S, Ciatti S et al. A recurrent homozygous nonsense mutation within the LAMA3 gene as a cause of Herlitz junctional epidermolysis bullosa in patients of Pakistani ancestry: evidence for a founder effect. J Invest Dermatol 1996; 106:781-4.
8. McGrath JA, Pulkkinen L, Christiano AM et al. Altered laminin 5 expression due to mutations in the gene encoding the beta 3 chain (LAMB3) in generalized atrophic benign epidermolysis bullosa. J Invest Dermatol 1995; 104:467-74.
9. McLean I, Irvine AD, Hamill KJ et al. An unusual N-terminal deletion of the laminin α3a isoform leads to the chronic granulation tissue disorder laryngo-onycho-cutaneous syndrome. Hum Mol Genet 2003; 12:2395-409.
10. Nakano A, Chao SC, Pulkkinen L et al. Laminin 5 mutations in junctional epidermolysis bullosa: molecular basis of Herlitz vs. non-Herlitz phenotypes. Hum Genet 2002; 110:41-51.
11. Allen BR. Thalidomide. Br J Dermatol 2001; 144:227-8.
12. Chave TA, Finlay AY, Knight AG. Thalidomide usage in Wales: the need to follow guidelines. Br J Dermatol 2001; 144:310-15.
13. Sampaio EP, Sarno EN, Galilly R et al. Thalidomide selectively inhibits tumour necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991; 173:699-703.
14. Kotoh T, Dhar DK, Masunaga R et al. Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice. Surgery 1999; 125:536-44.
15. Or R, Feferman R, Shoshan S. Thalidomide reduces vascular density in granulation tissue of subcutaneously implanted polyvinyl alcohol sponges in guinea pigs. Exp Hematol 1998; 26:217-21.